HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations

J Antimicrob Chemother. 2003 Nov;52(5):776-81. doi: 10.1093/jac/dkg456. Epub 2003 Oct 16.

Abstract

Objectives: The objective was to study genotypic correlates of discordant interpretations of amprenavir (APV) resistance between a rules-based algorithm and either recombinant phenotype or virtual phenotype.

Methods: HIV resistance mutations found in patients from the GenPheRex study were interpreted with VGI-TRUGENE (version 5.0; VGI) and compared with either recombinant-phenotype (Antivirogram, r-PHT) or virtual-phenotype (Virtual-Phenotype, v-PHT) interpreted through Virco biological cut-offs.

Results: Among 180 samples available, 56 (31.1%) were discordant with the observed genotype interpretation results, as a result of being judged as sensitive by r-PHT or v-PHT but resistant by VGI (S/R). Only the I84V mutation was almost invariably found in concordant resistant isolates compared with S/R isolates (60% versus 0%, respectively; P < 0.0001). Notwithstanding this, the number of multi-protease inhibitor-associated mutations (PAMs) was significantly higher in the concordant resistant isolates; the prevalence of >3 PAMs was 56.52% versus 33.93% in R/R and S/R isolates, respectively (P = 0.01). Correspondence analysis confirmed the relevance of PAMs, although additional mutations appeared to be correlated with APV resistance.

Conclusions: The rate of discordance between rules-based and either r-PHT or v-PHT interpretations for APV was high. Mutation I84V and accumulation of >3 PAMs were found to be associated with resistance as interpreted with all systems tested. However, our results indicate that a number of mutations may have an impact on APV resistance, but that they are missed by current interpretation algorithms and this merits further investigations.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Algorithms
  • Carbamates
  • Drug Resistance, Viral / genetics*
  • Furans
  • Genotype
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV Protease / genetics
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • HIV-1 / genetics
  • Humans
  • Microbial Sensitivity Tests
  • Mutation
  • Phenotype
  • Prospective Studies
  • Sulfonamides / pharmacology*
  • Sulfonamides / therapeutic use
  • Treatment Outcome

Substances

  • Carbamates
  • Furans
  • HIV Protease Inhibitors
  • Sulfonamides
  • amprenavir
  • HIV Protease